37 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Feb 2027
Next term end
12
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2031 · High confidence
Also notable
Ends Jan 2031 · High confidence
Also notable
Ends Nov 2032 · High confidence
Formulations of Bendamustine
US 8,609,707
The most cited patent in this portfolio, cited by 55 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Formulations of Bendamustine
US 9,034,908
Cited by 42 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Fulvestrant formulations
US 9,180,088
Cited by 17 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Fulvestrant Formulations (US 10,363,259) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due Mar 29, 2027The maintenance fee for Formulations of Bendamustine (US 9,144,568) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Pemetrexed Formulations (US 11,793,813) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due May 10, 2027The maintenance fee for Fulvestrant formulations (US 9,180,088) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Formulations of Bendamustine (US 11,844,783) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Formulations of Bendamustine (US 11,872,214) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Formulations of Bendamustine (US 9,265,831) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 12 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Formulations of Bendamustine (2011) | 11 in force | to Jan 2031 |
| Formulations of Bendamustine (2013) | 10 in force | to Jan 2031 |
| Fulvestrant formulations | 3 in force | to Nov 2032 |
| Fulvestrant Formulations and Methods of Their Use | 2 in force | to Feb 2039 |
| Pemetrexed Formulations | 2 in force | to Feb 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D676,572 | Vial with Collar Label In force · High confidence | In force | High confidence | |
| US 7,589,106 | Alcohol Free Formulation of Argatroban In force · Medium confidence | In force | Medium confidence | |
| US 7,687,516 | Alcohol Free Formulation of Argatroban In force · Medium confidence | In force | Medium confidence | |
| US 9,801,892 | Fulvestrant Formulations In force · High confidence | In force | High confidence | |
| US 10,363,259 | Fulvestrant Formulations In force · High confidence | In force | High confidence | |
| US 8,609,707 | Formulations of Bendamustine In force · High confidence | In force | High confidence | |
| US 9,000,021 | Method of Treating Bendamustine-Responsive Conditions in Patients Requiring Reduced Volumes for Administration In force · High confidence | In force | High confidence | |
| US 9,034,908 | Formulations of Bendamustine In force · High confidence | In force | High confidence | |
| US 9,144,568 | Formulations of Bendamustine In force · High confidence | In force | High confidence | |
| US 9,265,831 | Formulations of Bendamustine In force · High confidence | In force | High confidence |
Also on record, not counted in the 37: 4 patents in force now held by others · 1 patent ended · 9 applications pending · 40 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.